Intramucosal Calprotectin Expression in Inflammatory Bowel Disease (IBD) and Non-IBD Colorectal Inflammation


  • Ening Krisnuhoni Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Diah Rini Handjari Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Marini Stephanie Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Lydia Kencana Anatomical Pathology Residency Program, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Nur Rahadiani Department of Anatomical Pathology, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia



Inflammatory bowel disease, Non-IBD colitis, Intramucosal calprotectin


BACKGROUND: Inflammatory bowel disease (IBD) diagnosis remains a challenge accompanied with high numbers of misdiagnosis causing suboptimal management. Tons of trials have been conducted to improve the diagnostic accuracy, one of which is the use of biomarker such as calprotectin. Calprotectin can be detected in tissue (intramucosal) and is becoming a potential marker of IBD.

AIM: This study aims to determine intramucosal calprotectin expression in IBD, non-IBD colitis, and control.

METHODS: This analytic retrospective study included consecutively sampled IBD and non-IBD colitis colorectal biopsy specimens, and control group obtained from Cipto Mangunkusumo Hospital registered from 2017 to 2019. Cases were included in the study if specimens were indicative of IBD and non-IBD clinically and histopathologically and no abnormality were found histopathologically in the control group. Specimens with non-adequate data from the hospital medical records or with missing tissue slides were excluded from the study. Calprotectin immunostaining was conducted to evaluate mean intramucosal calprotectin expression (cell/HPF) in each group.

RESULTS: Most of the samples from IBD and non-IBD group (45 samples each) showed mild active inflammation. Mucosal calprotectin expression in aforementioned groups was higher than that of control group (p < 0.001). Subjects with active inflammation showed higher calprotectin expression compared to those with inactive inflammation (p < 0.001). Calprotectin expression was also related to activity grade.

CONCLUSION: Higher calprotectin expression showed significant association with the presence of inflammation and disease activity. However, the application of intramucosal calprotectin immunohistochemistry test to determine inflammatory etiology (IBD vs. non-IBD) still needs to be further evaluated.


Download data is not yet available.


Metrics Loading ...

Plum Analytics Artifact Widget Block


Chandra S, Simadibrata M. Management of inflammatory bowel disease. Indones J Gastroenterol Hepatol Dig Endosc. 2014;15:111-4.

Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and pathophysiology of inflammatory bowel disease. Clin Microbiol Rev. 2002;15(1):79-94. PMid:11781268 DOI:

Moore M, Feakins R, Lauwers G. Non-neoplastic colorectal disease biopsies: Evaluation and differential diagnosis. J Clin Pathol. 2020;73(12):783-92. PMid:32737191 DOI:

Manceau H, Chicha-Cattoir V, Puy H, Peoc’h K. Fecal calprotectin in inflammatory bowel diseases: Update and perspectives. Clin Chem Lab Med. 2017;55(4):474-83. PMid:27658156 DOI:

Guirgis M, Wendt E, Wang LM, Walsh A, Burger D, Bryant RV, et al. Beyond histological remission: Intramucosal calprotectin as a potential predictor of outcomes in ulcerative colitis. J Crohns Colitis. 2017;11:460-7. DOI:

Poullis A, Foster R, Mendall MA, Fagerhol MK. Emerging role of calprotectin in gastroenterology. J Gastroenterol Hepatol. 2003;18(7):756-62. PMid:12795745 DOI:

Averill MM, Kerkhoff C, Bornfeldt KE. S100A8 and S100A9 in cardiovascular biology and disease. Arterioscler Thromb Vasc Biol. 2012;32(2):223-9. PMid:22095980 DOI:

Chatzikonstantinou M, Konstantopoulos P, Stergiopoulos S, Kontzoglou K, Verikokos C, Perrea D, et al. Calprotectin as a diagnostic tool for inflammatory bowel diseases. Biomed Rep. 2016;5(4):403-7. PMid:27699005 DOI:

D’Angelo F, Felley C, Frossard JL. Calprotectin in daily practice: Where do we stand in 2017? Digestion. 2017;95(4):293-301. PMid:28511188 DOI:

Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, et al. Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization. Int J Mol Med. 2018;41:107-18. PMid:29115397 DOI:

Fabian O, Hradsky O, Lerchova T, Mikus F, Zamecnik J, Bronsky J. Limited clinical significance of tissue calprotectin levels in bowel mucosa for the prediction of complicated course of the disease in children with ulcerative colitis. Pathol Res Pract. 2019;215(12):1-6. PMid:31679791 DOI:

Eidan AJ, Iqbal MN, Mahdi LH. Immunohistochemistry study of expression of TNF-α, TRAF-1, and TRAF-2 in patients suffer from ulcerative colitis. Int J Adv Res. 2015;3:604-20.

Bass JA, Friesen CA, Deacy AD, Neilan NA, Bracken JM, Shakhnovich V, et al. Investigation of potential early histologic markers of pediatric inflammatory bowel disease. BMC Gastroenterol. 2015;15:129. DOI:

Yamamoto-Furusho JK, Ascaño-Gutiérrez I, Furuzawa-Carballeda J, Fonseca-Camarillo G. Differential expression of MUC12, MUC16, and MUC20 in patients with active and remission ulcerative colitis. Mediators Inflamm. 2015;2015:659018. PMid:26770020 DOI:

El-Bassat H, AboAli L, Yamany SE, Shenawy HA, Din RAA, Taha A. Interleukin-23p19 expression in patients with ulcerative colitis and its relation to disease severity. Adv Dig Med. 2016;3:88-94. DOI:

Chen P, Zhou G, Lin J, Li L, Zeng Z, Chen M, et al. Serum biomarkers for inflammatory bowel disease. Front Med (Lausanne). 2020;7:123. PMid:32391365 DOI:

Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ, et al. European consensus on the histopathology of inflammatory bowel disease. J Crohns Colitis. 2013;7(10):827-51. PMid:23870728 DOI:

Patil DT, Odze RD. Biopsy diagnosis of colitis: An algorithmic approach. Virchows Arch. 2018;472(1):67-80. PMid:29177895 DOI:

Feakins RM. Inflammatory bowel disease biopsies: Updated British society of Gastroenterology reporting guidelines. J Clin Pathol. 2013;66(12):1005-26. PMid:23999270 DOI:

Villanacci V, Reggiani-Bonetti L, Caprioli F, Saragoni L, Salviato T, Mescoli C, et al. Histopathology of inflammatory bowel disease-position statement of the pathologists of the Italian group for the study of inflammatory bowel disease (IG-IBD) and Italian group of gastrointestinal pathologists (GIPAD-SIAPEC). Dig Liver Dis. 2020;52(3):262-7. PMid:31884010 DOI:

Villanacci V, Reggiani-Bonetti L, Salviato T, Leoncini G, Cadei M, Albarello L, et al. Histopathology of IBD Colitis. A practical approach from the pathologists of the Italian Group for the study of the gastrointestinal tract (GIPAD). Pathologica. 2021;113(1):39-53. PMid:33686309 DOI:

Kencana L, Rahadiani N, Stephanie M, Handjari DR, Krisnuhoni E. Specimen adequacy and clinicopathological evaluation of inflammatory bowel disease colorectal biopsies in CiptoMangunkusumo Hospital Jakarta. Indones J Gastroenterol Hepatol Dig Endosc. 2021;22:100-5. DOI:

Bjarnason I. The use of fecal calprotectin in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2017;13:53-6.

Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: A link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13(2):279-84. PMid:14973103 DOI:

Tibble J, Sigthorsson G, Foster R, Sherwood R, Fagerhol M, Bjarnason I. Faecalcalprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49(3):402-8. PMid:11511563 DOI:

Turvill J, Aghahoseini A, Sivarajasingham N, Abbas K, Choudhry M, Polyzois K, et al. Faecal calprotectin in patients with suspected colorectal cancer: A diagnostic accuracy study. Br J Gen Pract. 2016;66(648):e499-506. PMid:27266863 DOI:

Kopi TA, Shahrokh S, Mirzaei S, Aghdaei HA, Kadijani AA. The role of serum calprotectin as a novel biomarker in inflammatory bowel diseases: A review study. Gastroenterol Hepatol Bed Bench. 2019;12:183-9. PMid:31528300

Leach ST, Yang Z, Messina I, Song C, Geczy CL, Cunningham AM, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42(11):1321-31. PMid:17852869 DOI:

Brookes MJ, Whitehead S, Gaya DR, Hawthorne AB. Practical guidance on the use of faecal calprotectin. Frontline Gastroenterol. 2018;9(2):87-91. PMid:29588834 DOI:

Salman YJ, Ali CA, Razaq AA. Fecal calprotectin among patients infected with some protozoan infections. Int J Curr Microbiol Appl Sci. 2017;6:3258-74. DOI:

Larsson G, Shenoy KT, Ramasubramanian R, Thayumanavan L, Balakumaran LK, Bjune GA, et al. Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India. United European Gastroenterol J. 2014;2(5):397-405. PMid:25360318 DOI:

Larsson G, Shenoy KT, Ramasubramanian R, Thayumanavan L, Balakumaran LK, Bjune GA, et al. High faecal calprotectin levels in intestinal tuberculosis are associated with granulomas in intestinal biopsies. Infect Dis (Lond). 2015;47:137-43. PMid:25522183 DOI:

Jung SH, Kang SG, Lee KM. The usefulness of fecal calprotectin in diagnosis and follow-up of intestinal tuberculosis: Prospective multicenter study. Am J Gastroenterol. 2017;112:S99. DOI:

Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study. Gastroenterology. 2007;133:1099-105. PMid:17919486 DOI:

Marchal-Bressenot A, Scherl A, Salleron J, Peyrin-Biroulet L. A practical guide to assess the Nancy histological index for UC. Gut. 2016;65(11):1919-20. PMid:27566129 DOI:

Colman RJ, Rubin DT. Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: A systematic review. Intest Res. 2016;14(3):202-10. PMid:27433141 DOI:

Langner C, Magro F, Driessen A, Ensari A, Mantzaris GJ, Villanacci V, et al. The histopathological approach to inflammatory bowel disease: A practice guide. Virchows Arch. 2014;464(5):511-27. PMid:24487791 DOI:

Geboes K, Riddell R, Öst A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47(3):404-9. PMid:10940279 DOI:

Carvalho AT, Elia CC, de Souza HS, Elias PR, Pontes EL, Lukashok HP, et al. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J Clin Gastroenterol. 2003;36(2):120-5 PMid:12544193 DOI:

Dubucquoi S, Janin A, Klein O, Desreumaux P, Quandalle P, Cortot A, et al. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn’s disease. Gut. 1995;37(2):242-6. PMid:7557575 DOI:

Magro F, Lopes J, Borralho P, Lopes S, Coelho R, Cotter J, et al. Comparing the continuous Geboes Score with the Robarts Histopathology Index: Definitions of histological remission and response and their relation to faecal calprotectin levels. J Crohns Colitis. 2020;14(2):169-75. PMid:31504348 DOI:




How to Cite

Krisnuhoni E, Rini Handjari D, Stephanie M, Kencana L, Rahadiani N. Intramucosal Calprotectin Expression in Inflammatory Bowel Disease (IBD) and Non-IBD Colorectal Inflammation. Open Access Maced J Med Sci [Internet]. 2022 Apr. 8 [cited 2023 Mar. 28];10(A):872-8. Available from:

Funding data